IMerge是一项在低风险骨髓增生异常综合征和贫血患者中使用依美特司他与安慰剂对照的3期研究。

{"title":"IMerge是一项在低风险骨髓增生异常综合征和贫血患者中使用依美特司他与安慰剂对照的3期研究。","authors":"Rami S Komrokji","doi":"10.1080/14796694.2025.2565877","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"3237-3244"},"PeriodicalIF":2.6000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Plain language summary of IMerge, a Phase 3 study of imetelstat versus placebo in people with lower-risk myelodysplastic syndromes and anemia.\",\"authors\":\"Rami S Komrokji\",\"doi\":\"10.1080/14796694.2025.2565877\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":12672,\"journal\":{\"name\":\"Future oncology\",\"volume\":\" \",\"pages\":\"3237-3244\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14796694.2025.2565877\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/10/12 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2025.2565877","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/10/12 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}